文献速递骨肿瘤关节外科

全股骨肿瘤假体置换的失效机制与生存率

Mechanisms of failure and survival of total femoral endoprosthetic replacements.
PubMed 文献 · Bone Joint J · 2019-01-01

回顾性分析1976至2017年81例全股骨肿瘤假体置换患者,5年和10年无翻修生存率分别为71%和63.3%,感染为主要失效机制(18%),既往手术史(HR 3.7)和近端胫骨相关关节置换(HR 3.8)为独立失效因素。

要点

  • 5年无翻修生存率71%,10年63.3%,3例假体达15年未翻修。
  • 感染占失效机制18%,肿瘤切除后初次重建假体感染率8%,低于翻修假体25%(p=0.001)。
  • 既往手术史(HR 3.7;p=0.041)和近端胫骨相关关节置换(HR 3.8;p=0.034)为独立失效因素。

核心结论

  • 全股骨肿瘤假体置换为股骨大量骨缺损提供可靠重建选择,假体作为初次植入物时生存良好。
  • 作者认为膝关节旋转铰链和髋关节双动轴承可能足以降低机械性和软组织失效风险。
  • 感染仍是主要问题,证据不足以支持常规使用银涂层假体。

研究设计与样本

  • 回顾性评估1976年至2017年81例接受全股骨肿瘤假体置换的患者,按Henderson分类对失效进行归类。
  • 38例女性(47%)和43例男性(53%),诊断时平均年龄43岁(12至86岁),平均随访时间10.3年(0至31.7年)。
  • 进行生存分析,随后采用单因素和多因素Cox回归识别独立假体生存因素。

主要发现

  • 假体无翻修生存率5年为71%,10年为63.3%,3例假体达15年未翻修。
  • 平均肌肉骨骼肿瘤协会评分26分(23至28)。
  • 失效机制:感染18%,结构失效6%,肿瘤进展5%,无菌性松动2%,软组织失效1%。
  • 肿瘤切除后初次重建假体感染率8%,低于翻修假体25%(p=0.001)。
  • 银涂层与非银涂层假体感染率相似(17.4% vs 19.%;p=0.869);髋关节脱位发生率10%;旋转铰链假体失效率为5.3%,低于固定铰链假体11%。

关键数值与推荐

  • 假体无翻修生存率:5年71%,10年63.3%。
  • 肿瘤切除后初次重建假体感染率8% vs 翻修假体25%(p=0.001)。
  • 银涂层假体感染率17.4% vs 非银涂层19.%(p=0.869)。
  • 旋转铰链假体失效率5.3% vs 固定铰链假体11%。
  • 既往手术史HR 3.7(p=0.041),近端胫骨相关关节置换HR 3.8(p=0.034)。

临床怎么用

  • 全股骨肿瘤假体置换可作为股骨大量骨缺损的可靠重建选项,假体作为初次植入物时生存良好。
  • 作者认为膝关节旋转铰链和髋关节双动轴承可能足以降低机械性和软组织失效风险。
  • 感染仍是主要问题,证据不足以支持常规使用银涂层假体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to evaluate the prosthesis characteristics and associated conditions that may modify the survival of total femoral endoprosthetic replacements (TFEPR). PATIENTS AND METHODS: In all, 81 patients treated with TFEPR from 1976 to 2017 were retrospectively evaluated and failures were categorized according to the Henderson classification. There were 38 female patients (47%) and 43 male patients (53%) with a mean age at diagnosis of 43 years (12 to 86). The mean follow-up time was 10.3 years (0 to 31.7). A survival analysis was performed followed by univariate and multivariate Cox regression to identify independent implant survival factors. RESULTS: The revision-free survival of the implant was 71% at five years and 63.3% at ten years. Three prostheses reached 15 years without revision. The mean Musculoskeletal Tumor Society score in the group was 26 (23 to 28). The mechanisms of failure were infection in 18%, structural failures in 6%, tumour progression in 5%, aseptic loosening in 2%, and soft-tissue failures in 1%. Prostheses used for primary reconstruction after oncological resections had lower infection rates than revision implants (8% vs 25%; p = 0.001). The rates of infection in silver-coated and non-silver-coated prosthesis were similar (17.4% vs 19.%; p = 0.869). The incidence of hip dislocation was 10%. Rotating hinge prosthesis had a lower failure rate than fixed hinge prosthesis (5.3% vs 11%). After Cox regression, the independent factors associated with failures were the history of previous operations (hazard ratio (HR) 3.7; p = 0.041), and the associated arthroplasty of the proximal tibia (HR 3.8; p = 0.034). At last follow-up, 11 patients (13%) required amputation. CONCLUSION: TFEPR offers a reliable reconstruction option for massive bone loss of the femur, with a good survival when the prosthesis is used as a primary implant. The use of a rotating hinge at the knee and dual mobility bearing at the hip may be adequate to reduce the risk of mechanical and soft-tissue failures. Infection remains the main concern and there is insufficient evidence to support the routine use of silver-coated endoprosthesis. Cite this article: Bone Joint J 2019;101-B:522-528.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Medellin MR, Fujiwara T, Clark R, et al. Mechanisms of failure and survival of total femoral endoprosthetic replacements. Bone Joint J. 2019. PMID: 31038993. doi:10.1302/0301-620X.101B5.BJJ-2018-1106.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。